IUdR/BUdR Cell Cycle Labelling

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

28 participants

Study Classification

INTERVENTIONAL

Study Start Date

1992-05-31

Study Completion Date

2002-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To determine cell cycle parameters and changes after treatment, the labelling agent is given and a bone marrow aspiration is accomplished before treatment and after treatment for comparison. Participants must be undergoing concurrent therapy for hematologic malignancy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Pilot Study to Determine Effects of the Btk Inhibitor PCI-32765 on Leukemia Cell Kinetics and Trafficking, Using Heavy Water Labeling in Subjects With CLL and SLL

NCT01752426

Leukemia

COMPLETED PHASE1/PHASE2

Pharmacokinetics of Daunorubicin in Young Patients With Cancer

NCT00673257

Unspecified Childhood Solid Tumor, Protocol Specific

COMPLETED NA

Dosimetry Study of I-131-CLR1404 in Patients With Relapsed or Refractory Advanced Solid Tumors

NCT00925275

Solid Tumors

COMPLETED PHASE1

Irinotecan in Treating Aging Patients With Solid Tumors

NCT00026195

Unspecified Adult Solid Tumor, Protocol Specific

COMPLETED PHASE1

Diindolylmethane in Healthy Volunteers

NCT00392652

Healthy, no Evidence of Disease

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Cell cycle parameters include LI, Ts, Tc, T dpot, changes in these parameters, and differences between normal and leukemic cells in patients with hematologic malignancy prior to and following treatment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hematologic Malignancies

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Chemotherapy for hematologic malignancy

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Histologic proof of one of:

* AML, ALL, or AUL
* MDS or CMML
* CML
* OR undergoing bone marrow transplantation.

Participants should be:

* off therapy for at least two weeks
* At least 18 years old or older
* Using adequate contraception if of child-bearing capability.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No